Which has higher valuation and earnings, ANNX or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is ANNX or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Structure Therapeutics N/A -24.91% -23.67%

Is ANNX or RCUS more profitable?

Annexon has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Arcus Biosciences -156.36% -68.97% -35.27%

Is RLAY or ANNX more profitable?

Relay Therapeutics' return on equity of -43.94% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Annexon N/A -101.19% -75.99%

Do analysts prefer GMTX or ANNX?

Annexon has a consensus price target of $16.00, suggesting a potential upside of 203.03%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Annexon 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has stronger earnings & valuation, GMTX or ANNX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is GMTX or ANNX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Annexon N/A -101.19% -75.99%

Which has preferable earnings & valuation, ANNX or ALMS?

Annexon has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Alumis $8.40M 371.91 -$243.32M -$1.98 N/A

Is ANNX or ALMS more profitable?

Annexon has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Alumis -2,825.70% -88.79% -70.72%

Annexon (ANNX) Competitors

$5.28 +0.24 (+4.76%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$5.22 -0.06 (-1.08%)

As of 06/23/2026 07:51 PM Eastern

Compare

ANNX vs. GPCR, RCUS, RLAY, GMTX, and ALMS

Should you buy Annexon stock or one of its competitors? MarketBeat compares Annexon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annexon include Structure Therapeutics (GPCR), Arcus Biosciences (RCUS), Relay Therapeutics (RLAY), Gemini Therapeutics (GMTX), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Annexon compare to Structure Therapeutics?

Annexon (NASDAQ:ANNX) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Structure Therapeutics' return on equity of -24.91% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Structure Therapeutics	N/A	-24.91%	-23.67%

91.8% of Structure Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Annexon currently has a consensus price target of $16.00, indicating a potential upside of 203.03%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 142.37%. Given Annexon's higher probable upside, equities analysts plainly believe Annexon is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

In the previous week, Structure Therapeutics had 2 more articles in the media than Annexon. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Annexon. Annexon's average media sentiment score of 0.00 equaled Structure Therapeutics'average media sentiment score.

Company	Overall Sentiment
Annexon	Neutral
Structure Therapeutics	Neutral

Annexon has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, indicating that its stock price is 235% less volatile than the broader market.

Summary

Structure Therapeutics beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Annexon compare to Arcus Biosciences?

Annexon (NASDAQ:ANNX) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Arcus Biosciences had 1 more articles in the media than Annexon. MarketBeat recorded 1 mentions for Arcus Biosciences and 0 mentions for Annexon. Arcus Biosciences' average media sentiment score of 1.71 beat Annexon's score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Annexon	Neutral
Arcus Biosciences	Very Positive

92.9% of Arcus Biosciences shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Annexon has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Annexon has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A

Annexon currently has a consensus price target of $16.00, suggesting a potential upside of 203.03%. Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 24.64%. Given Annexon's higher probable upside, equities research analysts plainly believe Annexon is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Annexon has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Arcus Biosciences beats Annexon on 8 of the 15 factors compared between the two stocks.

How does Annexon compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Relay Therapeutics' return on equity of -43.94% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Annexon	N/A	-101.19%	-75.99%

Relay Therapeutics presently has a consensus price target of $23.30, suggesting a potential upside of 33.60%. Annexon has a consensus price target of $16.00, suggesting a potential upside of 203.03%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Relay Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 1 mentions for Relay Therapeutics and 0 mentions for Annexon. Relay Therapeutics' average media sentiment score of 0.00 equaled Annexon'saverage media sentiment score.

Company	Overall Sentiment
Relay Therapeutics	Neutral
Annexon	Neutral

Relay Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Annexon has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	217.68	-$276.48M	-$1.57	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Relay Therapeutics beats Annexon on 9 of the 14 factors compared between the two stocks.

How does Annexon compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Annexon has a consensus price target of $16.00, suggesting a potential upside of 203.03%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Gemini Therapeutics' return on equity of -38.78% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Gemini Therapeutics' average media sentiment score of 0.00 equaled Annexon'saverage media sentiment score.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Annexon	Neutral

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Summary

Gemini Therapeutics beats Annexon on 6 of the 11 factors compared between the two stocks.

How does Annexon compare to Alumis?

Annexon (NASDAQ:ANNX) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Annexon has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Alumis	$8.40M	371.91	-$243.32M	-$1.98	N/A

Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Alumis has a beta of -0.55, suggesting that its stock price is 155% less volatile than the broader market.

In the previous week, Annexon's average media sentiment score of 0.00 equaled Alumis'average media sentiment score.

Company	Overall Sentiment
Annexon	Neutral
Alumis	Neutral

Annexon presently has a consensus target price of $16.00, suggesting a potential upside of 203.03%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 64.42%. Given Annexon's higher probable upside, equities analysts plainly believe Annexon is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Annexon has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Alumis	-2,825.70%	-88.79%	-70.72%

Summary

Annexon and Alumis tied by winning 6 of the 12 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$825.77M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-4.33	19.75	24.92	23.98
Price / Sales	N/A	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.72	8.29	10.79	6.50
Net Income	-$206.69M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.88%	2.87%	1.00%	-0.14%
1 Month Performance	-0.56%	2.19%	0.42%	0.77%
1 Year Performance	115.51%	55.48%	29.70%	28.49%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	2.8125 of 5 stars	$5.28 +4.8%	$16.00 +203.0%	+121.8%	$825.77M	N/A	N/A	60	High Trading Volume
GPCR Structure Therapeutics	2.2105 of 5 stars	$44.51 -1.1%	$106.75 +139.8%	+106.4%	$3.16B	N/A	N/A	136
RCUS Arcus Biosciences	3.3554 of 5 stars	$24.39 +1.1%	$35.10 +43.9%	+225.7%	$3.07B	$247M	N/A	500	Positive News
RLAY Relay Therapeutics	2.3656 of 5 stars	$15.88 +2.1%	$23.30 +46.7%	+439.9%	$3.04B	$15.35M	N/A	330	Gap Down High Trading Volume
GMTX Gemini Therapeutics	N/A	$70.21 +0.5%	N/A	+37.2%	$3.04B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. GPCR, RCUS, RLAY, GMTX, and ALMS

How does Annexon compare to Structure Therapeutics?

Summary

How does Annexon compare to Arcus Biosciences?

Summary

How does Annexon compare to Relay Therapeutics?

Summary

How does Annexon compare to Gemini Therapeutics?

Summary

How does Annexon compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. GPCR, RCUS, RLAY, GMTX, and ALMS

How does Annexon compare to Structure Therapeutics?

Which has higher valuation and earnings, ANNX or GPCR?

Is ANNX or GPCR more profitable?

Do insiders & institutionals have more ownership in ANNX or GPCR?

Do analysts recommend ANNX or GPCR?

Does the media favor ANNX or GPCR?

Which has more volatility and risk, ANNX or GPCR?

Summary

How does Annexon compare to Arcus Biosciences?

Does the media favor ANNX or RCUS?

Do insiders and institutionals hold more shares of ANNX or RCUS?

Which has more volatility & risk, ANNX or RCUS?

Which has stronger earnings and valuation, ANNX or RCUS?

Do analysts recommend ANNX or RCUS?

Is ANNX or RCUS more profitable?

Summary

How does Annexon compare to Relay Therapeutics?

Is RLAY or ANNX more profitable?

Do analysts recommend RLAY or ANNX?

Does the media refer more to RLAY or ANNX?

Which has more volatility and risk, RLAY or ANNX?

Do institutionals and insiders believe in RLAY or ANNX?

Which has higher valuation & earnings, RLAY or ANNX?

Summary

How does Annexon compare to Gemini Therapeutics?

Do insiders & institutionals have more ownership in GMTX or ANNX?

Which has stronger earnings & valuation, GMTX or ANNX?

Do analysts prefer GMTX or ANNX?

Is GMTX or ANNX more profitable?

Does the media refer more to GMTX or ANNX?

Which has more volatility & risk, GMTX or ANNX?

Summary

How does Annexon compare to Alumis?

Which has preferable earnings & valuation, ANNX or ALMS?

Which has more volatility & risk, ANNX or ALMS?

Does the media refer more to ANNX or ALMS?

Do analysts recommend ANNX or ALMS?

Is ANNX or ALMS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools